ATE477803T1 - Metabolit von quetiapine - Google Patents

Metabolit von quetiapine

Info

Publication number: ATE477803T1
Authority: AT; Austria
Prior art keywords: quetiapine; metabolite
Prior art date: 2003-07-02

Application number

AT04743131T

Other languages

English (en)

Inventor

Scott Grimm

Helen Winter

Patricia C Davis

Raymond F Suckow

Jeffrey Goldstein

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-02

Filing date

2004-06-28

Publication date

2010-09-15

2004-06-28 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE477803T1 publication Critical patent/ATE477803T1/de

Links

239000002207 metabolite Substances 0.000 title 1
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical class C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04743131T 2003-07-02 2004-06-28 Metabolit von quetiapine ATE477803T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48436503P	2003-07-02	2003-07-02
PCT/GB2004/002783 WO2005002586A1 (en)	2003-07-02	2004-06-28	Metabolite of quetiapine

Publications (1)

Publication Number	Publication Date
ATE477803T1 true ATE477803T1 (de)	2010-09-15

Family

ID=33563981

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04743131T ATE477803T1 (de)	2003-07-02	2004-06-28	Metabolit von quetiapine

Country Status (20)

Country	Link
US (1)	US20050026900A1 (de)
EP (1)	EP1644005B1 (de)
JP (1)	JP2007516193A (de)
KR (1)	KR20060082037A (de)
CN (1)	CN1816339B (de)
AR (1)	AR045004A1 (de)
AT (1)	ATE477803T1 (de)
AU (1)	AU2004253334A1 (de)
BR (1)	BRPI0412127A (de)
CA (1)	CA2531284A1 (de)
DE (1)	DE602004028739D1 (de)
ES (1)	ES2349091T3 (de)
IL (1)	IL172616A0 (de)
IS (1)	IS8283A (de)
MX (1)	MXPA05013869A (de)
NO (1)	NO20060556L (de)
RU (1)	RU2005141060A (de)
TW (1)	TW200509944A (de)
UY (1)	UY28400A1 (de)
WO (1)	WO2005002586A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL164155A0 (en) *	2002-03-20	2005-12-18	Teva Pharma	Crystalline forms of quetiapine hemifumarate
CA2550735A1 (en)	2003-12-22	2005-07-14	Acadia Pharmaceuticals Inc.	Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2008021463A2 (en) *	2006-08-15	2008-02-21	Acadia Pharmaceuticals, Inc.	Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060081361A1 (en) *	2004-09-13	2006-04-20	Gabbey Lawrence W	Oil cooler with integral filter
EP1838325A1 (de) *	2005-01-07	2007-10-03	AstraZeneca AB	Neue verwendung von piperazin-1-yldibenzo [b,f][1,4]thiazepin oder seines pharmazeutisch annehmbaren salzes und orale pharmazeutische zusammensetzungen
AU2006231497A1 (en) *	2005-04-04	2006-10-12	Acadia Pharmaceuticals Inc.	Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
EP1869007A1 (de) *	2005-04-14	2007-12-26	Teva Pharmaceutical Industries Ltd	Verfahren zur herstellung von quetiapinfumaraten
WO2007004234A1 (en) *	2005-07-04	2007-01-11	Usv Limited	A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
JP2009516707A (ja) *	2005-11-18	2009-04-23	アストラゼネカ・アクチエボラーグ	固形製剤
US8389510B2 (en)	2005-11-18	2013-03-05	Astrazeneca Ab	Crystalline forms
US20090069291A1 (en) *	2005-11-18	2009-03-12	Astrazeneca Ab	Salt Forms
JP2009516708A (ja) *	2005-11-18	2009-04-23	アストラゼネカ・アクチエボラーグ	液体製剤
EP1951257A4 (de) *	2005-11-18	2008-11-05	Astrazeneca Ab	Kristalline formen
WO2008079839A1 (en) *	2006-12-20	2008-07-03	Astrazeneca Ab	Compounds and uses thereof
WO2008118141A2 (en) *	2006-10-17	2008-10-02	Acadia Pharmaceuticals Inc.	Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
US20100056492A1 (en) *	2006-12-20	2010-03-04	Astrazeneca Ab	Compounds and uses thereof - 152
JP2010514682A (ja) *	2006-12-20	2010-05-06	アストラゼネカ・アクチエボラーグ	化合物及びその使用
EP2124957A4 (de) *	2007-03-22	2011-07-27	Astrazeneca Ab	Verfahren zur behandlung von gemütserkrankungen
CA2927380C (en)	2009-12-31	2017-07-04	Kempharm, Inc.	Amino acid conjugates of quetiapine, process for making and using the same
WO2011112657A1 (en)	2010-03-11	2011-09-15	Kempharm, Inc.	Fatty acid conjugates of quetiapine, process for making and using the same
CN102552128B (zh) *	2012-02-28	2013-09-18	陆荣政	一种富马酸喹硫平注射液及其制备方法
US9993486B1 (en)	2017-06-19	2018-06-12	Tlc Therapeutics, Llc	Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL140242B (nl) *	1963-03-01	1973-11-15	Wander Ag Dr A	Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1192812A (en) *	1966-05-20	1970-05-20	American Cyanamid Co	2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3539573A (en) *	1967-03-22	1970-11-10	Jean Schmutz	11-basic substituted dibenzodiazepines and dibenzothiazepines
US3966949A (en) *	1973-10-12	1976-06-29	Richardson-Merrell Inc.	Pharmaceutical compositions and preparing same
GB8607684D0 (en) *	1986-03-27	1986-04-30	Ici America Inc	Thiazepine compounds
US5661184A (en) *	1994-08-12	1997-08-26	Eli Lilly And Company	Psychiatric agents
US6342488B1 (en) *	1998-08-18	2002-01-29	Sepracor, Inc.	Phosphonorisperidone and sulforisperidone compositions and methods
AU2004206931A1 (en) *	2003-01-23	2004-08-05	Acadia Pharmaceuticals Inc.	Use of N-desmethylclozapine to treat human neuropsychiatric disease

2004
- 2004-06-28 MX MXPA05013869A patent/MXPA05013869A/es not_active Application Discontinuation
- 2004-06-28 RU RU2005141060/15A patent/RU2005141060A/ru not_active Application Discontinuation
- 2004-06-28 DE DE602004028739T patent/DE602004028739D1/de not_active Expired - Lifetime
- 2004-06-28 CA CA002531284A patent/CA2531284A1/en not_active Abandoned
- 2004-06-28 KR KR1020057025264A patent/KR20060082037A/ko not_active Withdrawn
- 2004-06-28 AT AT04743131T patent/ATE477803T1/de not_active IP Right Cessation
- 2004-06-28 BR BRPI0412127-9A patent/BRPI0412127A/pt not_active IP Right Cessation
- 2004-06-28 JP JP2006518324A patent/JP2007516193A/ja not_active Ceased
- 2004-06-28 EP EP04743131A patent/EP1644005B1/de not_active Expired - Lifetime
- 2004-06-28 CN CN2004800188710A patent/CN1816339B/zh not_active Expired - Fee Related
- 2004-06-28 WO PCT/GB2004/002783 patent/WO2005002586A1/en not_active Ceased
- 2004-06-28 AU AU2004253334A patent/AU2004253334A1/en not_active Abandoned
- 2004-06-28 ES ES04743131T patent/ES2349091T3/es not_active Expired - Lifetime
- 2004-07-01 US US10/883,024 patent/US20050026900A1/en not_active Abandoned
- 2004-07-02 AR ARP040102345A patent/AR045004A1/es not_active Application Discontinuation
- 2004-07-02 UY UY28400A patent/UY28400A1/es not_active Application Discontinuation
- 2004-07-02 TW TW093120058A patent/TW200509944A/zh unknown
2005
- 2005-12-15 IL IL172616A patent/IL172616A0/en unknown
2006
- 2006-02-01 IS IS8283A patent/IS8283A/is unknown
- 2006-02-02 NO NO20060556A patent/NO20060556L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2005002586A1 (en)	2005-01-13
DE602004028739D1 (de)	2010-09-30
JP2007516193A (ja)	2007-06-21
AR045004A1 (es)	2005-10-12
EP1644005B1 (de)	2010-08-18
KR20060082037A (ko)	2006-07-14
NO20060556L (no)	2006-04-03
ES2349091T3 (es)	2010-12-27
BRPI0412127A (pt)	2006-08-15
MXPA05013869A (es)	2006-02-28
TW200509944A (en)	2005-03-16
UY28400A1 (es)	2005-01-31
CA2531284A1 (en)	2005-01-13
US20050026900A1 (en)	2005-02-03
IL172616A0 (en)	2006-04-10
CN1816339B (zh)	2010-12-15
AU2004253334A1 (en)	2005-01-13
EP1644005A1 (de)	2006-04-12
IS8283A (is)	2006-02-01
WO2005002586A8 (en)	2006-02-09
CN1816339A (zh)	2006-08-09
RU2005141060A (ru)	2006-07-27

Legal Events

Date	Code	Title	Description
2011-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE602004028739D1 (de)	2010-09-30	Metabolit von quetiapine
EP1642377A4 (de)	2011-05-04	Vibrationseinrichtung
ITMI20041123A1 (it)	2004-09-03	Fissaggio
NO20043696L (no)	2004-11-05	Gamma-sekretaseinhibitorer
DK1472255T3 (da)	2006-07-10	Aza-arylpiperaziner
DE502004011575D1 (de)	2010-10-07	Verwendung von Dioldimerfettsäureestern
EP1560914A4 (de)	2007-05-30	Grasendophyten
ATE499348T1 (de)	2011-03-15	Stabiler polymorph von bifeprunoxmesilat
DE602004024640D1 (de)	2010-01-28	Reinigung von titantetrachlorid
ITMI20021327A1 (it)	2003-12-15	Nuove ossialchilpiperazine
ATE410417T1 (de)	2008-10-15	Kristallmodifikationen von triazinylaminostilbenen
ITMS20020001U1 (it)	2003-08-19	Help your self
ITMS20020001A1 (it)	2003-08-19	Help your self
UA8904S (uk)	2004-06-15	Комплект етикеток
UA9239S (uk)	2004-08-16	Комплект етикеток
UA7418S (uk)	2003-05-15	Комплект етикеток
UA8155S (uk)	2003-11-17	Комплект етикеток
UA9821S (uk)	2005-01-17	Комплект етикеток
UA8270S (uk)	2003-12-15	Комплект етикеток
UA9242S (uk)	2004-08-16	Комплект етикеток
UA8496S (uk)	2004-02-16	Комплект етикеток
UA7807S (uk)	2003-08-15	Комплект етикеток
UA6746S (uk)	2002-12-16	Кобза чотириструнна
FIU20020171U0 (fi)	2002-04-16	Puupalkki
SE0202366D0 (sv)	2002-08-02	Hjälpmedel